Heilind Electronics Now Offering Molex VersaBlade Wire-to-Wire Connector System

[ad_1]

Molex VersaBlade wire-to-wire connectors enable reliable signal and power transmission with superior mating reliability, polarization and easy harness assembly.

Heilind Electronics, a leading global distributor of electronic components and authorized distributor for Molex, is currently stocking the manufacturer’s VersaBlade wire-to-wire connectors. Featuring superior mating reliability, the connectors are easy to assemble and offer cost savings for white goods and HVAC applications.

In wire-to-wire applications, operators sometimes fail to ensure proper mating — which can lead to end-product failures. VersaBlade wire-to-wire connectors offer housings with polarization keys and terminals with dimples to help ease mating orientation identification. They also provide terminal position assurance (TPA) to ensure that terminals are fully locked in the correct position.

Rugged consumer and medical applications can be subject to shock, vibration or rough handling that can dislodge terminals and cause signal interference. To ensure customer design flexibility, Molex VersaBlade connectors come in a variety of circuit and cable sizes with different housing and TPA configurations.

Visit Heilind’s website for more information about Molex VersaBlade wire-to-wire connectors.

About Heilind Electronics

Heilind Electronics, Inc. (https://www.heilind.com) is one of the world’s leading distributors of connectors, relays, sensors, switches, thermal management and circuit protection products, terminal blocks, wire and cable, wiring accessories and insulation and identification products. Founded in 1974, Heilind has locations throughout the U.S., Canada, Mexico, Brazil, Germany, Singapore, Hong Kong and China.

Share article on social media or email:

[ad_2]

Innophos Releases New Data On The Benefits Of Chelated Minerals, Ahead Of Webinar

[ad_1]

Innophos Whitepaper Cover

“We are excited to share results of our latest research studying the benefits of chelation. Until now, there has been limited data that quantifies the benefits of chelation. In vitro studies show absorption advantage of Chelamax® zinc bisglycinate.”

Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of its latest whitepaper that builds upon the foundational work of their previous papers. The new whitepaper presents data from in vitro digestion studies that show the absorption advantage of Chelamax® zinc bisglycinate.

Innophos’ third research paper is part of an ongoing series focused on the benefits of chelated minerals. It will be presented by Dr. Robert Finn, Ph.D., Nutrition R&D Director at Innophos in an upcoming webinar on May 18th at 2:00-3:00pm EST on the SupplySide Network 365. “We are excited to share results of our latest research studying the benefits of chelation. Until now, there has been limited data that quantifies the benefits of chelation. Using an in vitro digestion model, we were able to mimic the gastrointestinal system to gain a complete view of solubility and absorption. Results quantify the magnitude of improved solubility and absorption, showcasing the concentration of chelated zinc absorbed under intestinal conditions, which was ten-fold higher than the concentration of zinc oxide.”

In this latest whitepaper, ‘Chelamax® Chelated Minerals Show Increased Absorption,’ Innophos compares the solubility and absorption of Chelamax® zinc bisglycinate vs. zinc oxide.

Key findings include:


  • Chelamax® zinc bisglycinate tablets are 10 times more bioaccessible in the stomach and five times more bioaccessible in intestinal conditions than zinc oxide.
  • Chelamax® zinc bisglycinate has an absorption rate that is 10 times greater than zinc oxide.
  • An in vitro digestion model suggests superior bioavailability of Chelamax® zinc bisglycinate over zinc oxide.

Innophos is committed to providing the highest quality, science-backed products, and has raised the bar in the chelated minerals industry in terms of validation and transparency with science-backed data.

To download the complimentary Chelamax® whitepaper click here.

To watch the webinar please register here.

Click here to learn more about how Chelamax® fully chelated minerals can help you get the most from your mineral supplements.

###

About Innophos

Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral, enzyme and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico and China. For more information, please visit http://www.innophos.com.

Share article on social media or email:

[ad_2]

Why You Should Try Bloom Nutrition’s New Ceremonial Grade Matcha Powder

[ad_1]

Bloom’s Founder, Mari Llewellyn, holds up new organic matcha tea powder.

“I created Mari’s Matcha because I wanted to make something that is a part of my everyday routine. Matcha is a ritual for me, and something I felt like the Bloomers would love as well,” said Bloom’s Founder, Mari Llewellyn.

Bloom Nutrition launches its new organic ceremonial grade matcha tea available for purchase on Bloom’s website and Amazon. This is Bloom’s first personalized wellness product collaboration with Mari Llewellyn, Bloom’s Founder.

“Mari’s Matcha” is crafted with 100% pure ceremonial grade matcha sourced directly from Kagoshima, Japan. Rich in antioxidants, including EGCg and chlorophyll, it helps boost metabolism and reduce stress, while naturally detoxifying the body.

“I created Mari’s Matcha because I wanted to make something that is a part of my everyday routine. Matcha is a ritual for me, and something I felt like the Bloomers would love as well,” said Bloom’s Founder, Mari Llewellyn.

Each serving of matcha contains 50 milligrams of natural caffeine and provides an energy boost without the crash or anxiety that comes with coffee. Its high concentration of L-theanine enhances focus and mental clarity allowing for a steady flow of calm energy.

Llewellyn said, “Anxiety is something I’ve battled for years, and coffee has always added to the problem. Matcha gives you an amazing slow-release energy and a calm focus. Plus it’s full of antioxidants and other health benefits.”

Matcha is a convenient alternative to coffee, plus it’s super easy to make. Simply mix the matcha powder with 2 ounces of warm water and then pour over 6 ounces of water or milk. Drinking Bloom’s matcha will naturally enhance daily energy levels and increase overall health benefits in one’s diet.

About Bloom Nutrition, LLC.

Bloom Nutrition is a female-owned company based in Santa Monica, California, committed to supporting women’s health from the inside, out. Creating a community of strong, driven and healthy women, Bloom carries a variety of fitness and wellness supplements geared to improving overall female health.

Check out Bloom Nutrition for more information and visit @bloomsupps to learn more.

Share article on social media or email:



[ad_2]

The International Society for Biological and Environmental Repositories (ISBER) Welcomes GenVault as a 2022 Diamond Sponsor

[ad_1]

We are proud to be considered among the nation’s largest and most secure biorepositories today and look forward to working with the ISBER community to further evolve best practice standards in sample management, preservation and transport.

The International Society for Biological and Environmental Repositories (ISBER) welcomes GenVault as a 2022 Diamond Sponsor. GenVault, a premier provider of bioinventory storage solutions and lab transport services, will exhibit at the ISBER Annual Meeting scheduled for May 17-20 in Atlanta, USA (http://www.isber.org/ISBER2022AnnualMeeting).

It’s an exciting time for biologic research and development, and commercial biorepositories such as GenVault play a crucial role in accelerating industry growth. By providing the quality space, securities, and support needed to safely store and transport important biologic materials and agents, GenVault is helping the scientific community and life science companies better utilize space and time in the lab; bring more lifechanging advances to market and achieve their missions faster. To learn more about GenVault’s bioinventory storage and transport services, visit https://genvault.com/.

“GenVault biorepositories are unlike any other,” said Keith DiMarino, President of GenVault and founder and CEO of DocuVault, a secure records archive company. “Our facilities are purpose-built by industry experts to preserve bioinventory for future generations and to protect those samples and specimens for life. When constructing our biorepositories and establishing our transport services, we use industry standards as the baseline and then we build even more securities on to that. We are proud to be considered among the nation’s largest and most secure biorepositories today and look forward to working with the ISBER community to further evolve best practice standards in sample management, preservation and transport.”

About GenVault

GenVault is a premier provider of bioinventory storage solutions and lab transport services. The headquarters, located in West Deptford, New Jersey, has the capacity to house more than 60,000,000 samples, over 1000 ultra-low-temperature units, and multiple expansive walk-in cold rooms. The state-of-the-art space can accommodate a wide range of storage conditions from ambient to cryogenic (LN2 vapor) and can be adapted to evolving storage needs. The convenient New Jersey location makes it easily accessible to the Philadelphia, New York, Baltimore, and Washington D.C. areas with proximity to multiple major airports, highways, and shipping hubs.

About the International Society for Biological and Environmental Repositories

ISBER advances the expertise and quality of biorepositories and biobanking science worldwide. Our vision is to be the leading network in the global biobanking and biorepository community.

ISBER fosters collaboration; creates education and training opportunities; provides a forum for the dissemination of state-of-the-art policies, processes, and research findings; and provides an international showcase for innovative technologies, products, and services. Together, these activities promote best practices that cut across the broad range of repositories that ISBER serves.

Share article on social media or email:

[ad_2]

Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic

[ad_1]

As the gene therapy pipeline expands…and in anticipation of rising regulatory requirements, our optimized and standardized CGMP manufacturing process is designed to meet robust CMC submissions for AAV gene therapy products, while providing customers with the advantage of shortened timelines.

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today introduced its new, UpTempo Virtuoso™ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes and streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.

The suspension-based UpTempo Virtuoso platform includes optimized standard protocols for cell culture, transfection, and downstream purification, as well as a standardized bill of materials to simplify the critical supply chain and material qualification. The new platform is designed to provide a CGMP-ready, high-titer process that is capable of yielding drug product for clinical evaluation in nine months, potentially reducing the conventional development pathway by half and affording more predictable outcomes. Customers using this new process will also have access to Catalent’s integrated supply chain of plasmid DNA (pDNA), offering further potential to reduce development timelines.

“As one of the first CDMOs to successfully develop a suspension-based transient transfection process, and our deep and specialized viral expertise and broad experience across more than 70 viral vector programs, we have built this new process with the goal of providing our customers with a reliable, reproducible, and scalable path to clinic,” said Manja Boerman, Ph.D., President, Cell & Gene Therapy at Catalent. “As the gene therapy pipeline expands to a broader disease portfolio, and in anticipation of rising regulatory requirements, our optimized and standardized CGMP manufacturing process is designed to meet robust CMC submissions for AAV gene therapy products, while providing customers with the advantage of shortened timelines.”

Catalent’s global network of pDNA and viral vector clinical and commercial facilities offer horizontally integrated solutions to support advanced therapy programs from gene to clinic. Its Maryland-based network includes viral vector programs in Baltimore and Gaithersburg, and commercial-scale manufacturing at its FDA- and EMA-approved facility in Harmans/BWI. Production of pDNA from research grade through to CGMP quality material is carried out at sites in Rockville, Maryland, and Catalent’s European Center of Excellence in Gosselies, Belgium.

About Catalent Cell & Gene Therapy

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vectors, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated development, clinical and commercial manufacturing facilities for small- and large-scale programs.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products annually. Catalent’s expert workforce exceeds 19,000, including more than 2,500 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

[ad_2]

Metrasens Launches Metrasens Ultra™ Detection System into Healthcare

[ad_1]

News Image

“In Metrasens Ultra we have concentrated on bringing to market a solution rather than just a product. The difference is that a solution represents a more complete response to the hospital’s needs holistically and serves the needs of all stakeholders”Dr. Simon Goodyear, CEO

Metrasens, a recognized leader in advanced detection technology for security and safety applications, today announced the launch of its next generation detection system, Metrasens Ultra™ with Xact ID™ intelligent detection technology for availability to the healthcare security market.

Metrasens Ultra, with limited release beginning in 2021, has now reached nearly 1,000 deployed systems around the world and has proven its efficacy in both detection performance as well as design aesthetics, both of which are key factors advocated for by cross functional hospital leadership.

The Rise of Violence in Healthcare

The American Association of Critical-Care Nurses (AACN) calls it “a weed with deep roots that keeps growing.” 80% of emergency room physicians say violence in healthcare has harmed patient care, according to a report by the American College of Emergency Physicians. Additionally, 50% say hospitals can do more by adding security such as metal detectors and visitor screening.

Behind these figures are real people – friends, family, co-workers, neighbors – who are having to deal with these acts of violence at their place of work daily. The development of Metrasens Ultra has taken into consideration the many ways all of these people have been affected, inclusive of, but not limited to, gun violence.

Threats Present in Many Forms, with Knives and Bladed Weapons Being the Untold Story Next to Guns

Violence is carried out in many forms – verbal and physical – with a weapon being utilized alongside some of the common forms. When it comes to the definition of a weapon, guns get the most attention, and rightfully so due to their deadly potential. Yet, in addition to guns, underlying threats exist that contribute significantly to concerns by hospital leaders – and those are knives or other bladed weapons.

A Metrasens hospital customer in the Midwest region of the U.S. reported the confiscation of thousands of knives over the course of several months, having deployed a Metrasens product following two incidents involving bladed weapons. One of those incidents required a life-saving surgery from the use of the weapon.

“Metrasens believes a comprehensive screening operation including people, process and technology must be taken into consideration to combat all threats in a safety-first culture such as a hospital or behavioral health hospital,” said Dr. Simon Goodyear, CEO of Metrasens. “We know that the solutions to these problems are not one-dimensional. They take orchestration which includes smart technology like Metrasens Ultra, but also the properly applied and trained use.”

Metrasens Ultra Combines Advanced Screening Technology + Carefully Defined Screening Processes + Simple Operation as the Trifecta for Success

Simply stated, Metrasens Ultra makes people screening suitable for healthcare facilities by allowing facilities to remain open and helpful rather than restricted and inaccessible— whilst maintaining proper aesthetics to feel appropriate for hospital environments.

Xact ID, Ultra’s unmatched technology component, was developed with system intelligence that drives performance through advanced software algorithms, machine learning, and sensor design. This results in excellent detection capability for a full range of threat items, including guns, knives, razor blades, and other concealable threat objects. This is all accomplished in a sleek, slender design that requires little footprint and no direct power source for flexible deployment in spaces often not designed for bulky security screening systems. Being an intelligent system, Metrasens Ultra increases in utility over time with software updates and upgrades. As needs for detecting threat items change, so too will Metrasens Ultra.

The technology is supported by carefully defined screening processes created collaboratively between Metrasens and customers. These processes take into consideration the targeted threat profiles, space/environment considerations, and the flow of foot traffic.

Usage of Metrasens Ultra by in-house or third-party security staff is a snap, with an intuitive user interface and easy to interpret zone indication LED’s that provide location on the body where a threat object is detected, taking away the guesswork and valuable time often wasted in secondary searches. Alert and operational activity data are captured automatically and stored for viewing on the user interface or downloaded into a report for management.

“In Metrasens Ultra we have concentrated on bringing to market a solution rather than just a product. The difference is that a solution represents a more complete response to the hospital’s needs holistically and serves the needs of all stakeholders. That is what we have done with Metrasens Ultra,” says Goodyear.

For more information about Metrasens Ultra visit: https://www.metrasens.com/metrasens-ultra/

Metrasens Ultra Image Gallery:

https://drive.google.com/drive/folders/1QIuNhk39NlqHQ4vC_aD8aus8Vo39rWiI?usp=sharing

About Metrasens

Metrasens is the world’s leading provider of advanced magnetic detection technologies. With a technology center and manufacturing facility in the United Kingdom, a North American sales and customer service hub in Chicago and a global network of distributors, the company’s innovative products are designed to address deficiencies in conventional screening methods and make the world safer and more secure. Metrasens’ mission is to take cutting-edge science from the laboratory and use it to create revolutionary, award-winning products that meet the distinct and diverse security needs of its customers. Metrasens’ core technologies have a wide range of real-world applications, embodied by solutions that are easy to adopt and simple to use. For more information, visit http://www.metrasens.com.

Share article on social media or email:

[ad_2]

Keys to Technology Transfer Success, Upcoming Webinar Hosted by Xtalks

[ad_1]

A high-level tech transfer process flow will be provided to showcase the complexities of the process.

Technology Transfer is a term that is widely used throughout many different industries. As a result, the definition and application of tech transfer can be rather broad. The general concept or idea of tech transfer may shift depending on the industry; however, the one common factor across these industries is the acknowledgement of tech transfer’s importance to the success of a project and to a much larger extent, a company’s business.

Over the course of this webinar, the featured speaker will take a deep dive into the biotechnology transfer process. The webinar will discuss the definition of technology transfer and will touch on the different industries where it is most commonly used. Specific details will be provided on how tech transfer applies to the contract manufacturing biotechnology industry and why it’s so important to the success of a project and business.

Overall, the speaker will present technology transfer as a very detailed and intricate process with many moving parts and groups involved. The webinar will discuss these different groups which provide significant input into the process and how these specific groups interact. A high-level tech transfer process flow will be provided to showcase the complexities of the process.

Join this webinar to learn the essential characteristics of a successful technology transfer process, how to ensure these keys are integrated into the process, common pitfalls within the different stages of tech transfer and how to avoid them while ensuring success.

Join Rob Carrier, MSAT Sr. Manager, Avid Bioservices, for the live webinar on Tuesday, May 24, 2022, at 1pm EDT.

For more information, or to register for this event, visit Communication Breakdown: Keys to Technology Transfer Success.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

[ad_2]

The Road Towards Clinical Implementation, Upcoming Webinar Hosted by Xtalks

[ad_1]

For many years, blood analyses for the same AD biomarkers were unattainable, but recent results have shown that they will become a reality.

Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) have become the cornerstone of the etiological diagnosis of AD. As such, AD biomarkers are indispensable for selection of the right patient groups in trials targeting AD. Moreover, other CSF biomarkers can provide important information on the effects of treatments on pathology, and for stratification.

For many years, blood analyses for the same AD biomarkers were unattainable, but recent results have shown that they will become a reality. Convincing data generated with new high-sensitivity assays have emerged with a remarkable consistency across different cohorts and independent of the analytical method used. Moreover, other neurodegenerative blood-based biomarkers, such as neurofilament light and more recently glial fibrillary acidic protein, provide information on disease progression and show potential for monitoring treatment effects.

Join this webinar to gain insights into the biomarkers for Alzheimer’s disease and get guidance for clinical implementation.

Join experts from Amsterdam UMC, Charlotte Teunissen, Professor in Neurochemistry, Chair of the Neurochemistry Lab; and Pieter van Bokhoven, Chief Scientific Officer, Head of the Industry Alliance Office of Amsterdam Neuroscience, for the live webinar on Tuesday, June 7, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Biomarkers for Alzheimer’s Disease: The Road Towards Clinical Implementation.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

[ad_2]

Data-Driven Insights for Effective Clinical Trial Oversight, Upcoming Webinar Hosted by Xtalks

[ad_1]

Join this webinar to learn how leveraging a modern data and analytics platform helps manage biomarkers and sample tracking data for improved trial oversight.

Leveraging a Platform Approach to Biomarkers and Patient Sample Tracking

Biomarkers are an increasingly common data source in clinical trials. They often come from specialty labs and are shared in varying formats from different vendors. Biomarker data can be resource-intensive to integrate with other sources due to variability and volume. Life sciences companies that rely on biomarker data to assess treatment efficacy know the ability to track samples in real-time is critical to the success of their trial. In this webinar, the featured speakers will share new methods, systems and analytics that automate the sample tracking process resulting in improved trial oversight and control.

The featured speakers will demonstrate how Jounce Therapeutics processed hundreds of samples daily utilizing a robust clinical data platform, the elluminate Clinical Data Cloud. elluminate helped Jounce keep up with their mass influx of data, enabling real-time insights and greater efficiencies by automating a previously manual tracking process.

Join this webinar to learn how leveraging a modern data and analytics platform helps manage biomarkers and sample tracking data for improved trial oversight.

Join expert speakers Lorenzo Balsamo, Associate Director of Clinical Informatics, Jounce Therapeutics; and Steve Taschereau, Business Intelligence Architect, eClinical Solutions, for the live webinar on Thursday, June 2, 2022, at 11am EDT (3pm GMT/UK).

For more information, or to register for this event, visit Data-Driven Insights for Effective Clinical Trial Oversight.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

[ad_2]

AsSeenOnTV.pro and Kevin Harrington Launch DRTV Campaign with Lewie

[ad_1]

Daily flossing is one of the easiest and least expensive ways you can improve your oral health, which directly affects your overall health. Developed by a dentist, and clinically proven to be more effective than a standard floss pick, Lewie helps people maintain healthy smiles.

Perfect for on-the-go, Lewie offers organic lip balm and multi-filamented dental floss in one convenient package. The lip balm is a blend of organic oils, shea butter, and beeswax complemented by herbal extracts. The multifilament floss is vegan wax coated, making it easy to guide between teeth and provide a superior clean. Plus, its flavors are designed to make flossing fun!

“Put your best smile forward wherever you go, with Lewie,” says Amanda Lewis, Founder of Lewie. “Your lips are going to love our organic balm. Plus, our multi-filamented dental floss will keep your smile healthy and fresh. We’re so excited to be working with AsSeenOnTV.pro and help even more people out of the classic dilemma of not having floss while they’re out and about!”

“Combining floss with lip balm and being able to fit them conveniently in your purse is a genius idea,” says Lisa Vrancken, Executive Vice President of AsSeenOnTV.pro. “I know Lewie has helped save a lot of selfies by enhancing smiles!”

As part of its DRTV campaign with AsSeenOnTV.pro, Lewie will be appearing in 30 second spots set to air nationwide and feature the original Shark himself, Kevin Harrington. AsSeenOnTV.pro is comprised of an award-winning team of producers, writers, videographers, and editors as well as industry veterans dedicated to finding the latest, most innovative products and ideas, and putting them on the DRTV map.

About AsSeenOnTV.pro

Headquartered in South Florida, AsSeenOnTV.pro is a full-service production, branding, and marketing company that specializes in direct response television, short- and long-form commercials, and brand building. Based out of a 25,000+ sq ft, state-of-the-art studio, the company’s creative team handles every aspect of production from script to screen to airing. For nearly two decades, AsSeenOnTV.pro’s veteran staff of writers, producers, videographers, and editors has amassed more than 50 Telly Awards, thousands of prestigious clients, and over $20 million in television placements.

About Kevin Harrington

As the inventor of the infomercial, founder of As Seen on TV, and one of the original Sharks on Shark Tank, Kevin Harrington has worked with some of the world’s biggest celebrities and launched some of the best-selling DRTV campaigns in history. Since producing his first 30-minute infomercial in 1984, Harrington has been involved in over 500 product launches that have resulted in over $5 billion in sales. Now, in his latest venture with AsSeenOnTV.pro, Harrington is on the hunt for the best new products and ideas, bringing them to homes everywhere through personalized DRTV campaigns featuring the Shark.

For more information on Lewie, please visit http://www.mylewie.com.

Share article on social media or email:

[ad_2]

Press Release News Wire Service